Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
UNRESECTABLE LOCALIZED NEUROBLASTOMA - IMPROVED SURVIVAL AFTER PRIMARY CHEMOTHERAPY INCLUDING CARBOPLATIN-ETOPOSIDE
Autore:
RUBIE H; MICHON J; PLANTAZ D; PEYROULET MC; COZE C; FRAPPAZ D; CHASTAGNER P; BARANZELLI MC; MECHINAUD F; BOUTARD P; LUTZ P; PEREL Y; LEVERGER G; DELUMLEY L; MILLOT F; STEPHAN JL; MARGUERITTE G; HARTMANN O;
Indirizzi:
CHU PURPAN,SERV MED INFANTILE B,UNITE HEMATOONCOL PEDIAT F-31059 TOULOUSE FRANCE
Titolo Testata:
British Journal of Cancer
fascicolo: 12, volume: 77, anno: 1998,
pagine: 2310 - 2317
SICI:
0007-0920(1998)77:12<2310:ULN-IS>2.0.ZU;2-0
Fonte:
ISI
Lingua:
ENG
Soggetto:
PEDIATRIC-ONCOLOGY-GROUP; II NEURO-BLASTOMA; MULTIMODALITY THERAPY; RADIATION-THERAPY; RESIDUAL DISEASE; FRENCH-SOCIETY; PROGNOSIS; DIAGNOSIS; SURGERY;
Keywords:
NEUROBLASTOMA; CARBOPLATIN; ETOPOSIDE; N-MYC;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
31
Recensione:
Indirizzi per estratti:
Citazione:
H. Rubie et al., "UNRESECTABLE LOCALIZED NEUROBLASTOMA - IMPROVED SURVIVAL AFTER PRIMARY CHEMOTHERAPY INCLUDING CARBOPLATIN-ETOPOSIDE", British Journal of Cancer, 77(12), 1998, pp. 2310-2317

Abstract

Neuroblastomas (NBs) were assessed according to INSS recommendations including MIBG scan and extensive bone marrow staging to eliminate metastatic spread. Patients with unresectable tumour received primary chemotherapy including two courses of carboplatin-etoposide (CE) and two of vincristine-cyclophosphamide-doxorubicin (CAdO). Post-operative treatment was to be given only in children over 1 year of age at diagnosis who had residual disease or lymph node (LN) involvement. Between 1990 and 1994, 130 consecutive children were registered. In comparison with resectable primaries, these tumours were more commonly abdominal, larger and associated with N-myc amplification (NMA), Complete, very good and partial response (CR, VGPR, PR) to CE were, respectively, 1%, 7% and 44% overall response rate (RR) to two courses of CE and two courses of CAdO was 71%, and the tumour could be removed in all but four of the children. The toxicity was manageable. The 5-year overall survival (OS) and event-free survival (EFS) were, respectively, 88% and 78% with a median follow-up of 38 months. In multivariate analysis, only NMA and LN involvement adversely influenced the outcome, particularly NMA, Children with unresectable NBs and no NMA fared as well as children with resectable ones as OS were, respectively, 95% and 99% and EFS 89% and 91%. Our data show encouraging results in localized but unresectable NBs as 90% of children may be considered as definitely cured, especially those without NMA.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 30/11/20 alle ore 16:08:22